NYSE:NVS - Novartis Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $78.78 -0.16 (-0.20 %) (As of 07/16/2018 06:00 AM ET)Previous Close$78.78Today's Range$78.5650 - $78.8952-Week Range$72.30 - $94.19Volume1.32 million shsAverage Volume1.90 million shsMarket Capitalization$182.57 billionP/E Ratio16.38Dividend Yield2.42%Beta0.75 Company ProfileFinancialsAnalyst RatingsDividend HistoryEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; and PEAR Therapeutics. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland. Receive NVS News and Ratings via Email Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNYSE:NVS CUSIPN/A Webwww.novartis.com Phone41-61-324-1111 Debt Debt-to-Equity Ratio0.33 Current Ratio1.17 Quick Ratio0.91 Price-To-Earnings Trailing P/E Ratio16.38 Forward P/E Ratio15.24 P/E Growth1.69 Sales & Book Value Annual Sales$49.11 billion Price / Sales3.72 Cash Flow$7.5388 per share Price / Cash10.45 Book Value$32.03 per share Price / Book2.46 Profitability EPS (Most Recent Fiscal Year)$4.81 Net Income$7.70 billion Net Margins16.04% Return on Equity16.23% Return on Assets8.69% Miscellaneous Employees121,597 Outstanding Shares2,317,460,000Market Cap$182,569.19 Novartis (NYSE:NVS) Frequently Asked Questions What is Novartis' stock symbol? Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS." How will Novartis' stock buyback program work? Novartis declared that its board has approved a stock buyback program on Saturday, April 8th 2017, which allows the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to purchase up to 2.9% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's leadership believes its shares are undervalued. How were Novartis' earnings last quarter? Novartis AG (NYSE:NVS) released its earnings results on Thursday, April, 19th. The company reported $1.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.25 by $0.03. The business had revenue of $12.69 billion for the quarter, compared to analysts' expectations of $12.45 billion. Novartis had a net margin of 16.04% and a return on equity of 16.23%. The company's revenue was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.13 earnings per share. View Novartis' Earnings History. When is Novartis' next earnings date? Novartis is scheduled to release their next quarterly earnings announcement on Wednesday, July, 18th 2018. View Earnings Estimates for Novartis. What price target have analysts set for NVS? 11 brokerages have issued 1 year price targets for Novartis' stock. Their predictions range from $90.00 to $91.00. On average, they expect Novartis' stock price to reach $90.50 in the next year. This suggests a possible upside of 14.9% from the stock's current price. View Analyst Ratings for Novartis. What is the consensus analysts' recommendation for Novartis? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 2 sell ratings, 8 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." Who are some of Novartis' key competitors? Some companies that are related to Novartis include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG). Who are Novartis' key executives? Novartis' management team includes the folowing people: Dr. Vasant Narasimhan, Chief Exec. Officer (Age 42)Mr. Harry Kirsch, Chief Financial Officer (Age 53)Mr. Steven Baert, Head of HR (Age 44)Mr. Richard Francis, Chief Exec. Officer of Sandoz (Age 50)Dr. James E. Bradner M.D., Pres of Novartis Institutes for Biomedical Research (Age 46) Has Novartis been receiving favorable news coverage? News articles about NVS stock have trended somewhat positive on Monday, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Novartis earned a news sentiment score of 0.12 on Accern's scale. They also assigned press coverage about the company an impact score of 46.06 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term. Who are Novartis' major shareholders? Novartis' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.32%), Manning & Napier Group LLC (0.16%), Park National Corp OH (0.01%), Gofen & Glossberg LLC IL (0.01%), Confluence Investment Management LLC (0.01%) and TNB Financial (0.01%). Company insiders that own Novartis stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Institutional Ownership Trends for Novartis. Which institutional investors are selling Novartis stock? NVS stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, Founders Capital Management, Pennsylvania Trust Co, Ledyard National Bank, Chesley Taft & Associates LLC, CENTRAL TRUST Co, Atria Investments LLC and Beacon Financial Group. View Insider Buying and Selling for Novartis. Which institutional investors are buying Novartis stock? NVS stock was acquired by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Confluence Investment Management LLC, Park National Corp OH, Thompson Rubinstein Investment Management Inc. OR, Fulton Bank N.A., Gofen & Glossberg LLC IL, Raymond James Trust N.A. and Cardinal Capital Management Inc.. Company insiders that have bought Novartis stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Insider Buying and Selling for Novartis. How do I buy shares of Novartis? Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Novartis' stock price today? One share of NVS stock can currently be purchased for approximately $78.78. How big of a company is Novartis? Novartis has a market capitalization of $182.57 billion and generates $49.11 billion in revenue each year. The company earns $7.70 billion in net income (profit) each year or $4.81 on an earnings per share basis. Novartis employs 121,597 workers across the globe. How can I contact Novartis? Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected] MarketBeat Community Rating for Novartis (NYSE NVS)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 352 (Vote Outperform)Underperform Votes: 409 (Vote Underperform)Total Votes: 761MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/16/2018 by MarketBeat.com StaffFeatured Article: Are analyst ratings accurate?